AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Syncona plc, operating within the Financial sector, has reported key developments in its portfolio for the first quarter, despite a slight decrease in net assets. The company’s net assets fell to £1.16 billion from £1.24 billion as of 21 March, marking a 4.9% reduction in net asset value per share.
Portfolio Performance
The decline in net assets was largely attributed to a decrease in the share price of Autolus. However, this was partially counterbalanced by valuation increases in Beacon and Forcefield, along with gains from the capital pool and share buybacks. The life sciences portfolio was valued at £739 million, reflecting an 8.3% return.
During the quarter, Syncona allocated £23.3 million to its life sciences portfolio and invested £11 million in a share buyback program. This involved repurchasing 9.6 million shares at an average discount of 38.1% to net asset value, resulting in a slight increase in net asset value per share.
Strategic Investments and Developments
Syncona (LSE: SYNC)’s portfolio continued to progress, attracting significant external investments. Notable developments include a £10 million commitment from the Roche Venture Fund to Forcefield’s Series A financing round and a $170 million raise by Beacon in a Series B round, with Syncona contributing $42.5 million. The company also completed the sale of Clade to Century Therapeutics, receiving $9.3 million upfront.
Furthermore, Syncona increased its allocation to the share buyback program by £20 million, raising the total to £60 million. This move was based on the company’s assessment of the current share price.
Clinical Progress
In terms of clinical advancements, Syncona’s portfolio companies reported notable progress. Autolus provided positive data from its pivotal Phase 1b and 2 study for obe-cel in B-cell acute lymphoblastic leukaemia. Beacon initiated a Phase 2 and 3 trial for its X-Linked Retinitis Pigmentosa treatment, and Resolution and Spur advanced their trials for liver disease and Gaucher disease, respectively.
Looking forward, Syncona plans to allocate £150 million to £200 million into its portfolio by March of the following year, excluding share buybacks. The company remains focused on achieving critical capital access milestones and value inflection points, with expectations for significant net asset value growth by the end of 2026.
Company Outlook
Syncona remains well-funded to support its portfolio’s development and aims to deliver on its potential milestones. The company’s strategic efforts, including portfolio rebalancing and diversification, aim to provide a foundation for future progress and long-term value.
